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Abstract
Background Recently, we showed that the c.40_42delAGA
(p.Arg14del) mutation in the phospholamban (PLN) gene
can be identified in 10–15 % of Dutch patients with dilated
cardiomyopathy or arrhythmogenic cardiomyopathy. The
arrhythmogenic burden of the p.Arg14del mutation was
illustrated by the high rate of appropriate ICD discharges
and a positive family history for sudden cardiac death.
Methods Our goal was to evaluate the geographical distri-
bution and the origin of this specific mutation in the Neth-
erlands and to get an estimation of the prevalence in a Dutch
population cohort. Therefore, we investigated the postal
codes of the places of residence of PLN p.Arg14del
mutation carriers and places of birth of their ancestors. In
addition, a large population-based cohort (PREVEND) was
screened for the presence of this mutation.
Results By April 2012, we had identified 101 probands
carrying the PLN p.Arg14del mutation. A total of 358
family members were also found to carry this mutation,
resulting in a total of 459 mutation carriers. The majority
of mutation carriers live in the northern part of the Nether-
lands and analysing their grandparents’ places of birth indi-
cated that the mutation likely originated in the eastern part
of the province of Friesland. In the PREVEND cohort we
identified six heterozygous PLN p.Arg14del mutation car-
riers out of 8,267 subjects (0.07 %).
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Conclusion The p.Arg14del mutation in the PLN gene is the
most frequently identified mutation in Dutch cardiomyopa-
thy patients. The mutation that arose 575–825 years ago is
likely to have originated from the eastern part of the prov-
ince of Friesland and is highly prevalent in the general
population in the northern part of the Netherlands.
Keywords Cardiomyopathy . ARVC/D . DCM . Genetics .
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Introduction
Inherited cardiomyopathies are genetically heterogeneous
disorders of the heart which often develop during adoles-
cence or early adult life [1]. Cardiomyopathies are grouped
into different categories, based on their functional and mor-
phological properties and subdivisions can be made
according to the genetic basis [2, 3]. Genetic overlap be-
tween cardiomyopathies is well-recognised. Hypertrophic
cardiomyopathy (HCM) is characterised by a thickened wall
of the left ventricle [4], and mutations in any of nine genes
encoding sarcomeric proteins can be found in 30–65 % of
HCM patients worldwide [5–7]. However, mutations in
these genes can also be identified in 18 % of patients
with dilated cardiomyopathy (DCM) [8], which is
characterised by left ventricular dilatation and contractile
dysfunction. Arrhythmogenic right ventricular cardiomyop-
athy (ARVC) is another cardiomyopathy subtype,
characterised by fibrofatty replacement of cardiomyocytes,
primarily in the right ventricle [9]. In addition to this classic
right ventricular subtype, biventricular involvement and left
ventricular predominance have been described [10]. ARVC is
considered to be mainly a ‘disease of the desmosome’, a cell-
cell adhesion complex [11]. Screening of desmosomal
genes has identified mutations in 40-58 % of patients
diagnosed with ARVC, but also in 5 % of patients in a
DCM cohort from the United Kingdom [12–15]. The
observed clinical and genetic overlap between ARVC
and DCM has led to the postulation of arrhythmogenic
cardiomyopathy as the encompassing entity [16].
Of the cardiomyopathies, DCM is genetically the most
heterogeneous; in addition to the sarcomere genes, more than
30 genes have been identified in DCM families [17]. One of
the genes implicated in DCM encodes phospholamban (PLN),
a calcium handling protein in the sarcoplasmic reticulum of
cardiac muscle [18]. A number of mutations have been iden-
tified, leading to a highly variable phenotype, ranging from
cardiac death in early adulthood tomiddle-aged asymptomatic
mutation carriers [19, 20].
The yield from screening cardiomyopathy populations
for PLN mutations is generally very low, ranging from
0.08 % to 0.38 % in selected cohorts [21–25].
Surprisingly, we identified the PLN p.Arg14del mutation
not only in 13 % (31/240) of Dutch patients diagnosed
with DCM, but also in 12 % (12/97) of Dutch patients
diagnosed with ARVC [26]. The arrhythmogenic burden
of the p.Arg14del mutation was illustrated by the high
rate of appropriate ICD discharges and a positive family
history for sudden cardiac death. Furthermore,
p.Arg14del mutation carriers more frequently underwent
cardiac transplantation, compared with patients with fa-
milial DCM [26]. Cascade screening has identified
dozens of family members carrying the same mutation.
Both variable expression and age-dependent penetrance,
which are hallmarks of all inherited cardiomyopathies,
are characteristic of the p.Arg14del mutation.
Recurrent and founder mutations in the Netherlands caus-
ing cardiac disease have been described in this series of the
Netherlands Heart Journal [7, 27–30]. Here, we report our
analysis of the origin of the p.Arg14del mutation, both by
geographic region using postal code maps, and by age using
haplotype analysis. Furthermore, we screened a large
population-based cohort for the presence of the p.Arg14del
mutation to get an impression of the potential number of
mutation carriers in the Netherlands.
Materials & methods
Genetic evaluation
Sequencing analysis and haplotype analysis for the PLN
p.Arg14del mutation has been described elsewhere [26].
To estimate the age of the haplotype, the linkage disequilib-
rium between the mutation and recombinant microsatellite
markers was calculated and the recombination fraction from
the distances between the mutation and microsatellite
markers was determined, enabling estimation of the number
of generations since a mutation had occurred [31].
Postal code analysis
The postal codes of the places of residence of all PLN
p.Arg14del mutation carriers were plotted to study their
geographical distribution. To study the region where the
mutation likely originated, we used a scoring system based
on the birthplaces of the grandparents of the proband carry-
ing the PLN p.Arg14del mutation. Without any additional
genetic results, each grandparent had a chance of 1 in 4 of
being a carrier of the mutation and therefore a score of ¼
was applied to the postal code of each grandparent’s place of
birth. If it was known whether the mutation was inherited
either paternally or maternally, that pair of grandparents had
a chance of 1 in 2 of being a carrier of the mutation and a
score of ½ was applied to the postal codes of their places of
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birth. If it was proven which grandparent was the carrier of
the mutation, a score of 1 was applied to the postal code for
their place of birth. The sum of all the scores per postal code
area was plotted. These analyses were based on the PC2
code (the first two numbers of the postal code) of the
mutation carriers and their grandparents. Data were
visualised with MapInfo Professional (MapInfo, Toronto,
Canada).
Cohort study
A large population-based cohort from the city of Groningen, in
the north of the Netherlands, the Prevention of Renal and Vas-
cular ENd-stage Disease (PREVEND) cohort (N=8,267), was
screened for the presence of the PLN p.Arg14del mutation. The
PREVEND study was designed to prospectively investigate the
association between urinary albumin excretion and renal and
Table 1 Shared haplotype surrounding the PLN gene for the p.Arg14del mutation carriers from the Netherlands, Germany and the US
DCM Index patients
Marker Position D02 D04 D06 D08 D10 D12
D6S303 116.050K 235 235 233 233 227 235 235 235 233 233 227 233
PLN-650K 118.250K 394 396 394 390 394 390 394 394 394 394 394 394
PLN-200K 118.700K 439 439 439 439 439 443 439 445 439 443 439 437
PLN-50K 118.850K 288 288 288 294 288 294 288 296 288 286 286 284
PLN-R14del 118.900K + - + - + - + - + - + -
PLN+200K 119.100K 339 337 339 355 339 355 339 341 339 339 351 347
D6S304 119.450K 237 249 237 231 237 237 237 231 237 241 237 247
D6S412 120.550K 203 205 203 209 203 203 205 209 205 209 203 211
ARVC Index patients
Marker Position A01 A03 A05 A07 A09 A11
D6S303 116.050K 227 227 227 227 227 237 233 233 235 235 235 235
PLN-650K 118.250K 394 390 394 396 394 394 394 394 394 394 394 388
PLN-200K 118.700K 439 443 439 441 439 437 439 437 439 441 439 443
PLN-50K 118.850K 288 288 288 290 288 286 288 288 288 290 288 292
PLN-R14del 118.900K + - + - + - + - + - + -
PLN+200K 119.100K 339 339 339 353 339 355 339 349 339 337 339 335
D6S304 119.450K 237 249 237 249 237 235 237 249 237 249 237 237
D6S412 120.550K 203 203 203 205 203 203 203 195 203 205 203 205
Non-Dutch Index patients
Marker Position US Germany Greece
D6S303 116.050K 225 231 227 227 233 233
PLN-650K 118.250K 394 394 394 396 390 396
PLN-200K 118.700K 439 445 439 441 443 437
PLN-50K 118.850K 288 290 288 290 286 288
PLN-R14del 118.900K + - + - + -
PLN+200K 119.100K 337 337 339 339 355 355
D6S304 119.450K 237 249 237 245 241 249
D6S412 120.550K 203 207 205 195 203 209
The shared haplotype in a selection of PLN p.Arg14del probands is marked in grey.
For patient D12, the size of the first proximal marker (PLN−50 K) had most likely changed. For patients D12 and the one from the United States
(US), either the size of the first distal marker (PLN+200 K) had changed or a recombination had occurred. The identical haplotype, found in two
patients from the German pedigree published by Posch et al. [34], is also shown. Two PLN p.Arg14del mutation carriers from the Greek pedigree
published by Haghighi et al. [21] carried another haplotype, as shown in the box. The position on chromosome 6 is listed. DCM indicates dilated
cardiomyopathy; ARVC arrhythmogenic right ventricular cardiomyopathy.
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cardiovascular outcome in the general population. The study
protocol is described elsewhere [32, 33]. In the period 1997–
1998, 8592 participants were enrolled in the study and DNA
samples were available for 8267 participants. The PREVEND
study was approved by the local medical ethics committee and
conducted in accordance with the Declaration of Helsinki.
Mutation detection
The prevalence of the PLN p.Arg14del mutation
in the PREVEND cohort was evaluated using KASPar® PCR
SNP genotyping system (KBiosciences, Herts, UK). All the
8267 available DNA samples were screened for the mutation.
Results
Genetic evaluation
By April 2012, we had identified 101 unique probands
carrying the PLN p.Arg14del mutation. A total of 358
family members were found to carry the same mutation,
resulting in a total of 459 mutation carriers and an average
of 4.5 (range 1–17) mutation carriers per family.
Haplotype analysis was performed in 49 of the 101 Dutch
PLN p.Arg14del families and in three families from the United
States, Germany and Greece [26]. A shared haplotype for five
markers in a 1.2 Mb region surrounding PLN was found,
although patients from the Greek family with the p.Arg14del
mutation carried another haplotype (Table 1).Allowing 25 years
per generation, the age of the ‘Dutch’ haplotype containing the
mutation is estimated to be between 575 and 825 years old [26].
Postal code analysis
The geographic distribution of the place of residence of the
mutation carriers is plotted in Fig. 1, which shows that the
majority of the identified carriers live in the northern part of
the Netherlands and in the province of Noord-Holland, and that
the numbers decrease gradually towards the south.
To determine the origin of the Dutch founder haplotype
containing the PLN p.Arg14del mutation, we analysed the
place of birth of the proband’s grandparents and scored the
corresponding postal codes according to their chance of being
Fig. 1 Postal code map
showing the distribution of PLN
p.Arg14del mutation carriers in
the Netherlands. The number of
PLN p.Arg14del mutation
carriers per region is shown
(in parenthesis: the number of
postal code regions, 90 in total).
On average, each region
contains 180,000 inhabitants
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the grandparent carrying the mutation. Data on these places of
birth were available for 60 of the 101 probands and the results
are shown in Fig. 2. We found that the majority of ancestors
came from the eastern part of the province Friesland.
The phenotypes of PLN p.Arg14del mutation carriers
vary greatly, not only between families, but also within
the same family, as illustrated by the family shown in
Fig. 3a and Table 2. The proband III:1 was diagnosed
with ARVC at age 21. She sought medical attention
after experiencing palpitations. She presented with a
low-voltage ECG with ventricular bigeminy and mono-
morphic ventricular extrasystoles from the right ventric-
ular outflow tract (Fig. 3b). During the course of
9 years follow-up, she developed progressive heart fail-
ure and experienced several appropriate ICD discharges
because of ventricular tachyarrhythmias. She was placed
on the waiting list for a cardiac transplantation, but died
at age 30. Her mother, who also carried the PLN
p.Arg14del mutation, had recordings of non-sustained
VTs on 24 h Holter ECG monitoring, but her evaluation
was otherwise unremarkable. The grandfather, also a
mutation carrier, died at age 75 without ever seeking
medical attention because of possible cardiac problems.
The proband’s two sisters (age 30 and 27 when last
evaluated) were found to be carriers of the PLN
p.Arg14del mutation and are being monitored frequent-
ly, but have not experienced any symptoms, although
the oldest sister demonstrated 1100 premature ventricu-
lar complexes on 24 h Holter monitoring (Table 2).
Cohort study
In the PREVEND cohort we identified six heterozygous
PLN p.Arg14del mutation carriers out of 8267 subjects
(0.07 %). These PLN p.Arg14del mutation carriers (age
at baseline 48±16 years; 4 males) did not have a
clinically manifested cardiomyopathy at baseline. Three
mutation carriers were diagnosed with hypertension at
baseline, and three were diagnosed with diabetes
mellitus. One subject (male, age at baseline 69 years)
developed heart failure during the 10-year follow-up
period; the others had not experienced heart failure at
a mean age of 53.4 years. None of the six mutation carriers
were diagnosed with atrial fibrillation or left ventricular
Fig. 2 Postal code map
illustrating the likely origin of
the founder haplotype
containing the PLN p.Arg14del
mutation. The number of points
based on the grandparents’
birthplaces is shown
(in parenthesis: the number of
postal code regions, 90 in total).
On average, each region
contains 180,000 inhabitants.
The province of Friesland is
enclosed by the bold border
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hypertrophy on the ECG. The set-up of the database provided
no additional cardiological data.
Discussion
The p.Arg14del mutation in the PLN gene is the most
frequently identified mutation in cardiomyopathy patients
in the Netherlands and the single most identified mutation in
cardiomyopathy patients worldwide. Dutch mutation
carriers showed high rates of appropriate ICD discharges,
cardiac transplantation and a positive family history for
sudden cardiac death [26]. This mutation has also been
identified in cohorts in other countries, such as Germany,
Spain, Greece, Canada, and the United States [21, 22, 34, 35
and personal communications M. Gollob & R. Hamilton].
The German family and an ARVC patient from the United
States carried the same haplotype surrounding the PLN gene
as the patients from the Netherlands. The Greek patients
carried another haplotype, illustrating that the PLN
Fig. 3 (a) Pedigree of a family carrying the PLN p.Arg14del mutation,
illustrating the variability of the phenotype. Squares indicate male
family members, circles indicate female family members, slashes indi-
cate deceased, and the arrow points to the index patient. The solid
black symbol indicates proven ARVC, while open symbols indicate
clinically unaffected family members. Genotype results are shown by
the p.Arg14del mutation present (+) or absent (−). (b) Baseline ECG of
patient III:1, diagnosed with ARVC. The ECG shows signs of both
DCM and ARVC: low voltage, ventricular bigeminy with left branch,
left axis morphology (suggesting right ventricular outflow tract origin)
and negative T-waves in the precordial leads
Table 2 Clinical characteristics of the family members shown in Figure 3
ID Sex Age at 1st evaluation Results at 1st evaluation Follow-up Notes
I:1 M NA NA NA †75 years
I:2 F 77 years 24 h ECG showed PVCs; echocardiography
normal
NA
II:1 F 43 years 24 h-ECG showed non-sustained VT;
echocardiography normal
11 years No progression
II:2 F NA NA NA
III:1 F 21 years Low voltage ECG; abnormal SA-ECG;
15,000 PVCs on 24 h ECG; sustained
VT on EPS; fibrofatty replacement on
cardiac biopsy; diagnosed with ARVC;
ICD implanted
9 years †30 years; died of heart
failure while on waiting
list for HTx
III:2 F 20 years Family screening; no abnormalities 10 years 1,100 PVCs on 24 h ECG
III:3 F 17 years Family screening; no abnormalities 10 years Delivered a healthy boy
at 28 years
IV:1 M NA NA NA
EPS indicates electrophysiology study; HTx cardiac transplantation; ICD implantable cardioverter defibrillator; PVC premature ventricular
complex; SA-ECG signal averaged ECG; VT ventricular tachycardia. NA not available
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p.Arg14del mutation is recurrent, with at least two different
haplotypes identified. All the Dutch patients carried the
same haplotype and we estimated this haplotype to be
between 575 and 825 years old. Although we have identi-
fied the founder effect of the PLN p.Arg14del mutation in
the Netherlands, we cannot exclude that its origin is foreign,
due to immigration from Germany, Belgium, France or
Spain, for example, especially considering the age of the
mutation [36]. The emigration in the 19th and early 20th
century of PLN p.Arg14del mutation carriers from the Neth-
erlands or from other Northern European countries to the
United States and Canada has likely resulted in the presence
of this mutation in North America. Dutch mutation carriers
could also have emigrated to South Africa, Australia and
New Zealand. The presence of the p.Arg14del mutation
needs to be confirmed in genetic studies in these countries.
To estimate the geographical origin of the p.Arg14del
mutation, we used a scoring method based on the places
of birth of the probands’ grandparents. This scoring
system revealed the eastern part of the province Fries-
land as the most likely area of origin of the p.Arg14del
mutation in the Netherlands (Fig. 2). Most current mu-
tation carriers live in the northern part of the Nether-
lands including the province of Noord-Holland, i.e.
close to the origin of the mutation, and a gradual
decline towards the southern part of the Netherlands
can be seen in Fig. 1. As has been shown for other
founder mutations in the Netherlands, including some
described in this NHJ series [7, 27–30], the migration
of much of the Dutch population, and therefore muta-
tion carriers, has been fairly limited and the distribution
of current mutation carriers already gives a clear indi-
cation of its origin.
Following the identification of the p.Arg14del muta-
tion in cardiomyopathy patients, we sought to identify
whether the mutation was also present in a large
population-based cohort from the northern Netherlands
that had not been selected for the presence of cardio-
myopathy or other cardiac diseases. Six of 8267 sub-
jects (0.07 %) were identified as mutation carriers,
suggesting that the mutation could be present in ap-
proximately 1:1400 individuals in the northern part of
the Netherlands. Postal code analysis suggested a lower
frequency towards the south. By April 2012, the popu-
lation of the three northern provinces of Groningen,
Friesland and Drenthe was 1.7 million [37]. Given
these numbers, approximately 1250 PLN p.Arg14del
mutation carriers are suspected to live in these prov-
inces. The prevalence of the mutation in other prov-
inces is expected to be lower, but since they have
larger populations (e.g. 2.7 million in the province of
North Holland), the total number of Dutch PLN
p.Arg14del carriers is likely to be more than 2000.
Cascade family screening is ongoing and will probably
identify several hundred more carriers.
The age at inclusion (48±16 years) of these carriers
illustrates the age-dependent penetrance and variable
expression of the p.Arg14del mutation. Since the onset of
mutation-related symptoms (mean age 44.4 years) is well after
the start of their reproductive age [26], many mutation carriers
had already had children, explaining the continued high
prevalence of the mutation. This mean age is likely to be
biased, since the index patients usually mark the severe end
of the disease spectrum. Some index patients had had a child
who had died of sudden cardiac death at a much younger age
than their age of onset.
Following the arrhythmogenic profile of the PLN
p.Arg14del mutation, primary prevention by implanting
an ICD could be beneficial for mutation carriers. We
aim to determine the risk factors which will identify
individuals at high risk for life-threatening ventricular
arrhythmias. Identification of independent risk factors
would enable the selection of PLN p.Arg14del mutation
carriers who are most likely to benefit from an ICD,
while the absence of such risk factors in other carriers
would justify alternative treatment options. We have set
up the PHOspholamban RElated CArdiomyopathy
STudy (PHORECAST, www.phorecast.nl) to evaluate
the possible risk factors for life-threatening ventricular
arrhythmias. This study will be of great importance for
all p.Arg14del mutation carriers as well as their cardi-
ologists, who are faced with a great variability of symp-
toms and large clinical differences, both between and
within affected families.
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